LIPO has a new catalyst
Reuters: "Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research"
Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth
No FDA-approved therapy currently exists for OLP
Patient registry and OLP study information is now available
Triple Bottom holds the support.
Finaly breaks the minor order blocks with good volume
Once it clears 0.65$ resistance, 0,85$, 1.20$ and 1.50$ will be the target levels.
Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth
No FDA-approved therapy currently exists for OLP
Patient registry and OLP study information is now available
Triple Bottom holds the support.
Finaly breaks the minor order blocks with good volume
Once it clears 0.65$ resistance, 0,85$, 1.20$ and 1.50$ will be the target levels.
For alerts,special reports,news and singals over 15.000 + instruments our free discord channel
discord.gg/4DrmXHfvnG
About AI Discord Channel: bit.ly/470HjmP
Ücretsiz Discord Kanalımız
discord.gg/4DrmXHfvnG
discord.gg/4DrmXHfvnG
About AI Discord Channel: bit.ly/470HjmP
Ücretsiz Discord Kanalımız
discord.gg/4DrmXHfvnG
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.